Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Xuzhen Tang"'
Autor:
Yayi He, Haoyue Guo, Li Diao, Yu Chen, Junjie Zhu, Hiran C. Fernando, Diego Gonzalez Rivas, Hui Qi, Chunlei Dai, Xuzhen Tang, Jun Zhu, Jiawei Dai, Kan He, Dan Chan, Yang Yang
Publikováno v:
Engineering, Vol 15, Iss , Pp 102-114 (2022)
Patient-derived tumor xenografts (PDXs) are a powerful tool for drug discovery and screening in cancer. However, current studies have led to little understanding of genotype mismatches in PDXs, leading to massive economic losses. Here, we established
Externí odkaz:
https://doaj.org/article/ff5be0d86a244933aa0d0e66330b5f06
Autor:
Hong Xin, Ke Wang, Gang Hu, Fubo Xie, Kedong Ouyang, Xuzhen Tang, Minjun Wang, Danyi Wen, Yizhun Zhu, Xiaoran Qin
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e85308 (2014)
Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis worldwide and the molecular mechanism is not well understood. This study aimed to establish a collection of human HCC cell lines from patient-derived xenograft (PDX) models. From t
Externí odkaz:
https://doaj.org/article/1492cc0f37f1486984079837d2f53e2c
Publikováno v:
Molecules, Vol 21, Iss 8, p 1093 (2016)
Glutamate-mediated excitotoxicity is a major cause of ischemic brain damage. MK-801 confers neuroprotection by attenuating the activation of the N-methyl-d-aspartate (NMDA) receptor, but it failed in clinical use due to the short therapeutic window.
Externí odkaz:
https://doaj.org/article/08dd8fed682f4d4db5b44a41ab82cd98
Autor:
Xuzhen Tang, Jun Zhu, Chunlei Dai, Kan He, Yang Yang, Diego Gonzalez Rivas, Haoyue Guo, Yayi He, Hiran C. Fernando, Dan Chan, Li Diao, Junjie Zhu, Jiawei Dai, Yu Chen, Hui Qi
Publikováno v:
Engineering. 15:102-114
Patient-derived tumor xenografts (PDXs) are a powerful tool for drug discovery and screening in cancer. However, current studies have led to little understanding of genotype mismatches in PDXs, leading to massive economic losses. Here, we established
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df5f9786ff0823a1b8b4fe434430c2e8
https://doi.org/10.1016/j.eng.2021.06.017
https://doi.org/10.1016/j.eng.2021.06.017
Autor:
Hui, Qi, Xing, Zhang, Huanhuan, Liu, Meng, Han, Xuzhen, Tang, Shulan, Qu, Xiaoyu, Wang, Yifu, Yang
Publikováno v:
Journal of Cancer
Shikonin is a naphthoquinone pigment isolated from the root of Lithospermum erythrorhizon, which has displayed potent anti-tumor properties. However, the effects of shikonin in colorectal cancer cells have not been yet fully investigated. In this stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3388673a8d2b79a2e8c9842279b4e668
https://doi.org/10.7150/jca.65297
https://doi.org/10.7150/jca.65297
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70e355baab0d948e620e036a2ae76a05
https://doi.org/10.1136/jitc-2022-sitc2022.1017
https://doi.org/10.1136/jitc-2022-sitc2022.1017
Autor:
Xuzhen Tang, Yaqi Cui, Lanqiao Zhang, Huihui Jin, Zeqiong Xu, Hu He, Chongxun Ge, Song Liu, Xiaochun Yu, Song Shi
Publikováno v:
Cancer Research. 83:6184-6184
Although PARP inhibitors (PARPi) are very successful on the treatment of BRCA-mutant cancer, the tumor spectrum targeted by PARPi is quite narrow. Interestingly, Poly(ADP-ribose) Glycohydrolase (aka PARG), the major dePARylation enzyme, has emerged a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::050a4926bd4772bb7ea9f5fa7a7866e7
https://doi.org/10.1158/1538-7445.am2023-6184
https://doi.org/10.1158/1538-7445.am2023-6184
Autor:
Fuyang Wang, Yuying Yang, Haoxia Zhao, Chunlei Dai, Bingrui Han, Mengyao Zhang, Xia Xiong, Chao Zhang, Xuzhen Tang, Qunsheng Ji
Publikováno v:
Cancer Research. 82:5988-5988
Non-CNS metastatic brain cancer is about 10 times more common than CNS cancer. Lung cancer and breast cancer account for most brain metastasis. KRAS-mutant NSCLC compose a third lung adenocarcinoma, among which 17% to 55% will develop brain metastase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1836d2339ca0d004cadc2f331338d172
https://doi.org/10.1158/1538-7445.am2022-5988
https://doi.org/10.1158/1538-7445.am2022-5988
Autor:
Hui Qi, Xia Xiong, Huanhuan Liu, Yuying Yang, Chunlei Dai, Haoxia Zhao, Bingrui Han, Xuzhen Tang, Qunsheng Ji
Publikováno v:
Cancer Research. 82:5989-5989
Lung cancer is the leading cause of cancer-related death worldwide. Nearly 80% of lung cancers are non-small cell lung cancer (NSCLC) and 60% of them are diagnosed at the metastatic stage. Brain metastases affect more than 20% of NSCLC patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1092a3039edbad61f4ed7398966ee46d
https://doi.org/10.1158/1538-7445.am2022-5989
https://doi.org/10.1158/1538-7445.am2022-5989
Publikováno v:
Cancer Research. 82:6015-6015
There are a number of challenges associated with personalized medicines. For example, many models revolve around the question of whether or not the in vitro models capture the relevant in vivo pathobiology and drug response information that may impac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcae131ea9f1e33c821645c58c85c676
https://doi.org/10.1158/1538-7445.am2022-6015
https://doi.org/10.1158/1538-7445.am2022-6015